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ABSTRACT
Objective: Histiocytosis is a systemic disease that usually affects the central nervous system. The aim of this study is to discuss the
neuroimaging characteristics of Langerhans cell histiocytosis (LCH), the most common of these diseases; and the non-Langerhans cells
histiocytosis (NLCH), which includes entities such as hemophagocytic syndrome, Erdheim-Chester and Rosai-Dorfman diseases. Method:
Literature review and illustrative cases with pathologic confirmation. Results: In LCH, the most common findings are 1) osseous lesions in
the craniofacial bones and/or skull base; 2) intracranial, extra-axial changes; 3) intra-axial parenchymal changes (white and gray matter);
4) atrophy. Among the NLCH, diagnosis usually requires correlation with clinical and laboratory criteria. The spectrum of presentation
includes intraparenchymal involvement, meningeal lesions, orbits and paranasal sinus involvement. Conclusion: It is important the
recognition of the most common imaging patterns, in order to include LCH and NLCH in the differential diagnosis, whenever pertinent.
Keywords: Langerhans cells histiocytosis, non-Langerhans cells histiocytosis, Rosai-Dorfman, hemophagocytic syndrome, Erdheim-
Chester.
RESUMO
Objetivo: Histiocitose é uma doença sistêmica que, frequentemente, acomete o sistema nervoso central. Este trabalho propõe discutir as
características de neuroimagem da histiocitose de células de Langerhans (HCL), mais comum; e as histiocitoses não-Langerhans (HNL),
como a síndrome hemofagocítica, doenças de Erdheim-Chester e Rosai-Dorfman. Método: Revisão de literatura, com demonstração de
casos confirmados por anatomopatológico. Resultados: Na HCL os achados mais comuns são: 1) lesões ósseas craniofaciais e da base do
crânio; 2) lesões intracranianas, extra-axiais; 3) acometimento parenquimatoso intra-axial na substância cinzenta ou branca; 4) atrofia.
Dentre as HNL, o diagnóstico, em geral, exige correlação com critérios clínico-laboratoriais. O espectro de apresentação das mesmas
inclui acometimento intraparenquimatoso, lesões meníngeas, envolvimento orbitário e das cavidades paranasais. Conclusão: É
importante o reconhecimento dos padrões de imagem mais comuns, para que HCL e HNL sejam incluídas no diagnóstico diferencial,
sempre que pertinente.
Palavras-chave: Histiocitose de células de Langerhans, histiocitoses não-Langerhans, Rosai-Dorfman, síndrome hemofagocítica,
Erdheim-Chester.
Histiocytosis is a systemic disease that usually affects
many organs, including the central nervous system (CNS).
This group of disorders is characterized by an uncontrolled
histiocytic proliferation, usually of unknown etiology, which
triggers an immunologically mediated inflammatory process.
Eventually, external agents such as infectious processes or
neoplasms may be considered as the trigger factors.
The aim of this study is to discuss the neuroimaging
characteristics of Langerhans cell histiocytosis, the most
common of these diseases, and also the less common ones,
grouped under the category non-Langerhans cells histiocy-
tosis. This last group includes entities such as hemophago-
cytic syndrome, Rosai-Dorfman and Erdheim-Chester diseases.
Some of these diseases share imaging findings such as
extra-axial lesions, hypothalamic-pituitary axis involvement
and skull involvement. However, as it will be clear in the fol-
lowing sections, there are some differences that can help to
differentiate between them.
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Langerhans cell histiocytosis (LCH) is a rare systemic
granulomatous disease of the dendritic system with a
variable clinical course that may be encountered at any
age and may affect almost any organ1.
CNS involvement in LCH has been recognized since the
early reports of the disease because of the frequent involve-
ment of the cranial bones and the hypothalamic-pituitary
region (HPR) with diabetes insipidus (DI) as key manifesta-
tion. Less frequently, granulomatous lesions in the meninges,
the choroid plexus, the pineal gland, or the cerebral par-
enchyma can be encountered2.
In the past decades, a wide variety of other CNS findings
have been described since the advent of magnetic resonance
imaging (MRI), with or without associated clinical neuroen-
docrine findings.
The second most frequent presentation of CNS LCH,
excluding HPR disease, is a combination of pathologic
changes in the cerebellum, basal ganglia, and/or pons with
characteristic MRI patterns3. Results of histopathologic
examination of tissue from cerebellar biopsies and autopsies
of patients with such MR imaging changes revealed neuron
loss and axonal degeneration along with a profound T-cell
inflammation. Thus, the described MR imaging signal intens-
ity abnormalities were interpreted as indicative of a neuro-
degenerative process (ND)4.
Apart from the extension of these so-called ‘‘neurodegen-
erative’’ lesions, there are 2 other types of parenchymal
changes: (a) the frequently found dilated Virchow- Robin
spaces (VRS) and (b) the rare leukoencephalopathy pattern2.
Clinical features
The clinical presentation ranges from a single bone
lesion to widespread multiorgan involvement. The course
is unpredictable, with a spectrum of spontaneous
regression, chronic recurrences for years, or a rapidly
fatal deterioration5.
Intracranial lesions have been observed during the
course of disease in patients with a history of proved
LCH and also as the first and presenting LCH manifesta-
tions, in which case they can cause considerable diagno-
stic challenge3.
Four groups of patients can be clinically distinguished: 1)
those with a disorder of the hypothalamic-pituitary system;
2) patients presenting with site-dependent symptoms from
space-occupying lesions, such as seizures; 3) those who
exhibit a neurologic dysfunction mostly following a cerebel-
lar-pontine pathway involvement, including reflex abnormal-
ities, ataxia, intellectual impairment, tremor, or dysarthria
with variable progression to severe CNS deterioration; and
4) patients who present with an overlap of the symptoms
mentioned previously6.
Histopathologic findings
Typical granulomas consist of an accumulation of
Langerhans cells, indeterminate and interdigitating cells,
macrophages and T-lymphocytes, and variable numbers of
multinucleated giant cells and eosinophils. Birbeck granules
are present, and CD1a is immunoreactive4.
MRI findings and differential diagnosis
In LCH, the wide spectrum of cranial and intracranial MRI
findings include: 1) osseous lesions in the craniofacial bones
and/or skull base with or without soft-tissue extension; 2)
intracranial, extra-axial changes (involvement of hypothala-
mic-pituitary region, meninges, and other circumventri-
cular organs, including the pineal gland, choroid plexus, and
ependyma); 3) intra-axial parenchymal changes (white matter
and gray matter) with a predominance of a symmetric neuro-
degenerative pattern and; 4) cerebral atrophy3.
The most frequently encountered manifestation of LCH
in patients with localized or multisystem disease is the
granulomatous osseous lesion, most commonly affecting
the skull (Figure 1). These lesions are often osteolytic with
a sclerotic margin. Soft-tissue extension may be observed.
The differential diagnosis of lytic osseous lesions of the cal-
varia in childhood includes mostly neoplasm (metastases),
infectious/inflammatory (sarcoidosis, tuberculosis) and lep-
tomeningeal cyst. Lytic osseous lesions of the craniofacial
bones may also be observed in fibrous dysplasia, rhabdo-
myosarcoma, or severe mastoiditis7.
The most common CNS manifestation in LCH is infiltra-
tion of the hypothalamic pituitary region by LCH granuloma
(Figure 2), frequently leading to diabetes insipidus and
anterior pituitary hormone deficiency4. The characteristic
features consist of enlargement of the pituitary stalk with
potential progression to space-occupying tumors extending
to the pituitary and hypothalamus. Given the association
of DI with LCH, there can be also typically loss of the
physiologic hyperintense signal of the posterior pituitary
Figure 1. Langerhans cell hystiocitosis in a 19-year-old patient.
MR images in the axial plane, sequences FLAIR (A) and
postcontrast T1WI (B) disclose a lesion in the occipital bone,
with intermediate signal intensity in FLAIR (arrow in A) and
intense contrast enhancement (arrow in B).
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on T1-weighted images, which correlates with the loss of
antidiuretic hormone-containing granules. In addition,
threadlike narrowing of the infundibulum with a maximum
width less than 1 mm can be seen2.
The absence of hyperintensity in the posterior pituitary
and the presence of an infundibular or hypothalamic
mass are nonspecific findings. Differential diagnosis of
these findings is broad, including mostly: intracranial
tumors (germinomas), granulomatous diseases (sarcoi-
dosis, Wegener granulomatosis), leukemia, and autoim-
mune infundibuloneurohypohysitis8.
The high frequency of pineal cysts and enlarged pineal
glands in patients with LCH remains a nonspecific but strik-
ing observation; this may reflect direct pineal infiltration by
LCH or hyperplasia of the gland. The co-existing changes in
the pituitary and pineal regions might be caused by their
functional interactions, because both structures belong to
the circumventricular organs that are located outside the
blood brain barrier9.
Other space occupying tumoral lesions occur rarely
in the meninges (Figure 3), choroid plexus (Figure 4),
and in the brain parenchyma (Figure 5). These lesions
are typically characterized by signal intensity corre-
sponding to soft tissue, presenting intermediate inten-
sity on T1-weighted images (T1WI) and T2-weighted
images (T2WI) with moderate or marked homogeneous
contrast-enhancement).
Choroid-plexus lesions, which might otherwise mimic
papillomas, are characterized by a marked hypointensity
on T2WI (Figure 4). Differential diagnosis of intraparenchy-
mal CNS lesions includes germ cell tumor, craniopharyn-
gioma, sarcoidosis, or Rosai-Dorfman disease7.
Figure 2. Langerhans cell hystiocitosis in a patient with
diabetes insipidus. Sagittal T1WI image demonstrates a
thickened pituitary infundibulum and absence of the normal
T1-hyperintense posterior pituitary lobe (A). Enhanced sagittal
T1WI image demonstrates intense contrast enhancement of
the thickened infundibulum (B and arrow).
Figure 3. Patient with systemic Langerhans cell hystiocitosis. Axial T1WI (A), T2WI (B) and postcontrast T1WI (C). Extra-axial,
bilateral space-occupying lesions originating from the meninges (mainly dura mater) in the high convexity. There is marked
hypointensity in T2WI and intense contrast enhancement.
Figure 4. Langerhans cell hystiocitosis in a 5-year-old boy with
exophthalmos, polyuria, polydipsia, and skin lesions. MR
shows solid expansive lesions in the choroid plexus of both
ventricular atria, characterized by hypointensity on T2WI
(arrows in A) and intense contrast enhancement in corres-
ponding T1WI (B). Notice some white matter edema near the
atrium of the left lateral ventricle, associated to cystic areas
more evident in the postcontrast T1WI.
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In addition to granulomatous lesions, intracerebral
abnormalities also include progressive neurodegenerative
changes (ND-LCH) within the cerebellum, basal ganglia
and pons (Figure 5).
Neurodegenerative signal intensity abnormalities are a
rare consequence of LCH. The prevalence of radiologic
ND-LCH in pediatric patients with LCH is uncertain and
ranges in different reports between 4% and 10%. Recent
studies indicate that the radiologic ND-LCH is more fre-
quently detected in patients with craniofacial lesions or neu-
roendocrine problems10.
These degenerative changes are characterized by symmet-
rically increased signal intensity in T2-weighted sequences
within the cerebellar gray matter extending into adjacent
white matter and having hypo- or hyperintensity on T1-WI.
Pontine lesions have been reported as T2 hyperintense signal
abnormalities in the tegmentum or pyramidal tracts. In the
basal ganglia, the abnormalities consist of hyperintensities
on T1-weighted images and variable signal intensities on
T2-weighted images (Figure 6). These lesions present variable
contrast enhancement and usually little or no mass effect7.
Clinically, this pattern of involvement was associated
with a neurodegenerative syndrome of highly variable sever-
ity and course. The symptoms range from subtle tremor to
profound disabilities, including ataxia, dysarthria, and psy-
chomotor deterioration3.
Figure 5. Langerhans cell hystiocitosis patient with ataxia, diabetes insipidus and behavioral disturbances. Axial T1WI shows
hypointense lesions in the deep white matter of both cerebellar hemispheres (A and arrows). Coronal T2WI discloses the
hyperintensity of these lesions (B and arrows). Postcontrast axial T1WI demonstrates that the cerebellar lesions do not enhance;
however, there is nodular enhancement of a lesion in the anterior medulla (C and arrow).
Figure 6. The same patient as in Figure 5, images obtained at the basal ganglia level. Axial T1WI demonstrates that these lesions
are hyperintense (A and arrow). They are also hyperintense in a corresponding FLAIR image (B); and some of them clearly present
enhancement in a postcontrast axial T1WI at the same level (C and arrow).
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The MR signal intensity abnormalities in ND-LCH
are not pathognomonic for LCH. Similar findings can be
observed in the cerebellum of patients with cerebrotendi-
nous xanthomatosis, Erdheim-Chester disease, corticobasal
degeneration, or toxic demyelination. Symmetric hyperinten-
sities on T1-weighted images were also observed in the basal
ganglia of patients with chronic liver failure and in patients
with long-term parenteral nutrition10.
The white matter changes consist of two other patterns:
a perivascular pattern and a leukoencephalopathy pattern3.
Dilated Virchow-Robin spaces are best seen on T2WI and
can be barely visible with a width of approximately 2 mm.
The role of Virchow-Robin spaces in the pathophysiology
of CNS-LCH remains to be investigated. No biopsy samples
to confirm histopathology are available from such lesions,
but they might be consistent with either an active inflam-
matory process or the sequelae of an inflammatory process
following the distribution of the perivascular spaces2.
The leukoencephalopathy-like pattern involves the cere-
bellar white matter, the pons, and the periventricular white
matter and presents with symmetric patchy areas character-
ized by high signal intensity on T2WI and low signal intens-
ity on T1WI without a clear vascular distribution7. In most
cases, supratentorial lesions were confluent and predomi-
nantly periventricular, with blurred margins. Breakdown of
the blood brain barrier were only seen in a few severely dis-
abled patients3.
Differential diagnosis includes acute disseminated ence-
phalomyelitis, acute multiphasic disseminated encephalitis,
metabolic and degenerative disorders, or chemo-/radiation
therapy sequelae7.
Atrophic changes may be limited to the cerebellar hemi-
spheres but may also be global, usually in patients with a
progressive symptomatic course11.
ROSAI DORFMAN DISEASE
Rosai-Dorfman disease, also called ‘sinus histiocytosis
with massive lymphadenopathy’ (SHML), most commonly
affects young adults — males more often than females —
with a peak age around 20 years. It is a sporadic disease with
occasional clusters. Etiology is unknown. The lesional cell
derivation from circulating mononuclear cells suggests a
reactive disorder and the increased incidence of serum
auto-immune antibodies during active disease suggests a
possible pathogenic correlation with an immune regulatory
process compromise. HHV-6 and Epstein-Bar viruses have
been implicated in some cases12.
Clinical features
In its classic form, Rosai-Dorfman disease causes a
massive, painless cervical lymphadenopathy, fever, weight
loss and an elevated erythrocyte sedimentation rate. It is
the presenting symptom in the vast majority (approximately
90%) of cases. Inguinal and axillary lymphadenopathies are
less common (20%). Other sites of lymph node enlargement
involvement include mediastinum and upper para-aortic
nodes (10-15%)13.
Extranodal sites are involved simultaneously in about 43%
of cases and isolated extranodal RDD occurs in only 23% cases.
Irrespective of concurrent lymph node involvement, the most
frequent extranodal sites in decreasing order are skin/soft tis-
sue, nasal cavity/paranasal sinuses, orbit/eye/ocular adnexa,
bone, salivary gland, CNS, oral cavity, kidney/genitourinary
tract, respiratory tract, liver, tonsil, breast, gastrointestinal tract
and heart. Hepatosplenomegaly is uncommon14.
In exceedingly rare circumstances, CNS can be affected.
About 70% of intracranial cases had no lymphadenopathy
and 52% had no associated systemic disease. So, the classic
clinical presentation is not a requirement for the diagnosis.
Some scholars believe that the usage of this term SHML in
CNS is not quite appropriate because of the lack of lympha-
denopathy in the great majority of cases. The mean age at
onset is older in patients with intracranial RDD (mean
age: 39.4 years) than in systemic disease with massive lym-
phadenopathy. The sex distribution is 1.5: 1 (male: female)
in isolated intracranial disease. Intracranial RDD causes a
variety of symptoms, such as headache, seizure, numbness,
paraplegia, cranial nerve deficits and visual disturbances
depending on the location of the lesion (15). Symptoms of
hypothalamic pituitary axis dysfunction such as diabetes
insipidus were also described16.
The clinical course may be chronic or fluctuating but is
usually self-limiting, with 70% to 80% of individuals having
spontaneous resolution. The mortality rate is low but death
may result from CNS or renal involvement, immune dysfunc-
tion, and opportunistic infections17.
Histopathologic findings
The definitive diagnosis of Rosai-Dorfman disease relies
on a pathologic and immunohistochemical examination.
RDD is characterized by abundant sheets of large- and med-
ium-sized vacuolated histiocytes in a fibrous stroma, inter-
spersed with foci of chronic inflammatory cells. There are
numerous Russell bodies. A feature of the condition is the
presence of lymphophagocytosis (emperipolesis), that is
characteristic but not pathognomonic of RDD (in only 70%
of cases), although this may be less marked in intracranial
disease. The histiocytes typically stain positive for S100
and CD68 and negative for CD1a. Both T and B lymphocytes
are commonly present. The disease can be differentiated
from LCH in which eosinophils are conspicuous, the histio-
cytes do not exhibit emperipolesis, contain Birbeck granules
on electron microscopy, and are immunoreactive for CD1a,
these last two absent in RDD15,18,19.
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MRI findings and differential diagnosis
CNS involvement is unusual with or without nodal dis-
ease. The usual finding in this disease is an intracranial
extraaxial mass, although intraparenchymal and intraventri-
cular cases have been reported18.
Cases of spinal epidural or subdural masses are a rare
manifestation of RDD20. Intraparenchymal brain and intra-
medullary spinal cord lesion are even rarer21.
Intracranial involvement accounted for 75% and spinal
canal involvement for 25%. Frequent intracranial locations
of RDD include the cerebral convexities, parasagittal and
petroclival (Figure 7). Suprasellar region involvement is
extremely rare16. There have also been reports of cavernous
sinus invasion22.
Most lesions in intracranial Rosai-Dorfman disease
mimic meningioma in both clinical and radiologic aspects
(Figure 7), making the diagnosis more difficult. MRI reveals
well-defined dural-based lesions, single or multiple, with
hypointensity or isointensity on T1WI and T2WI, and with
marked homogeneous enhancement after the administra-
tion of gadolinium. Some lesions are associated with adja-
cent bone erosion19.
Perfusion-weighted techniques disclose decreased values
of relative cerebral blood volume inside the lesions. Rosai-
Dorfman disease is essentially a lymphoproliferative disorder
with no neoangiogenesis, as evidenced by histopathological
findings. That feature might be important for differentiating
the disease from meningiomas, hemangiopericytomas and
solitary fibrous tumors of the meninges, which typically have
markedly increased perfusion parameters. However, a recent
report has shown that Rosai-Dorfman disease may also
show increased perfusion due to its high positivity for
CD34 and CD31 antibodies, which are surrogate markers
for the intrinsic vascularization of lesions23.
The natural history of Rosai-Dorfman disease remains
uncertain, although most cases are benign and self-limited.
The spontaneous regression of Rosai-Dorfman disease was
reported in systemic disease, but not in intracranial lesions.
A few cases in the literature involved Rosai-Dorfman disease
of the CNS, with the regression of nonsurgically treated
lesions after the administration of corticosteroid agents19.
The excision of these lesions is normally undertaken to
confirm the diagnosis and reduce the mass effect.
Complete macroscopic excision is the goal of surgery, and
when this is achieved patients have a normal life expectancy
with no recurrent disease. Early and significant recurrence
has been reported in rare cases, which implies that this dis-
ease process may not always follow an indolent course24.
ERDHEIM-CHESTER DISEASE
The earliest Erdheim-Chester disease (ECD) is a rare,
sporadic, systemic, histiocytic disease of unknown etiology.
It is pathologically characterized by xanthogranulomatous
infiltrate and clinically and radiologically defined by bone
involvement, which is a constant and pathognomic finding25.
ECD generally affects the long bones of the lower limbs.
Related radiographic findings are diffuse or patchy opacities
of the tibia and/or fibula, medullary sclerosis and cortical
thickening of the metaphyseal and diaphyseal portions with-
out epiphyseal changes. On 99 mTc scintigraphy, intense,
Figure 7. A 46-year-old patient diagnosed with Rosai Dorfman disease. Axial T2WI shows a large petroclival extra-axial lesion,
with marked hypointensity, extending into the right temporal fossa, prepontine and right cerebellopontine cisterns (A). There is
mass effect on the corresponding temporal lobe and brainstem, with associated vasogenic edema. Axial T1WI demonstrates
isointensity (B). Postcontrast axial T1WI depicts marked enhancement of the mass (C).
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bilateral and symmetrical tracer uptake by the long-bone
diaphyses and metaphyses are revealed, reflecting increased
osteoblastic activity in those regions26.
Clinical features
Erdheim-Chester disease affects both genders, though
with a slight male predilection. It has a peak incidence
between the fifth and sixth decade of life, although it may
manifest at any age. ECD is a progressive disease that has
a 5-year survival rate of 41%26. The most common presenting
symptom is bone pain, fever and weight loss. Physical
examination reveals no consistent findings; however, hyper-
tension has commonly been noted. Laboratory evaluation
also tends to reveal unremarkable findings; however, abnor-
mal levels of neutral fat, free fatty acids, and triglycerides
have been reported27.
About half of all patients have extraskeletal manifesta-
tions. The disease can affect multiple organs systems, includ-
ing musculoskeletal, CNS, pulmonary and renal systems.
Retroperitoneal involvement is secondary to infiltration of
the fat and surrounding structures by histiocytes and asso-
ciated fibrosis causing renal impairment. The cardiovascular
manifestations of ECD have occurs in about 40% of the
patients with periaortic “fibrosis” as the most frequent
cardiovascular involvement. Other manifestations include
heart failure, valvular dysfunction, renovascular hyperten-
sion and pericarditis. The pulmonary involvement manifests
as dyspnea or a dry cough. Most patients have mediastinal
infiltration, diffuse interstitial infiltrates and pleural and/or
interlobar septal thickening best seen on high-resolution
computed tomography28.
Alterations of the skin and mucosae and nodal involve-
ment are present in ECD, even though it tends to be more
extensive in LCH27. The cutaneous involvement show
xanthomas and xanthelasmas, more commonly present in
the patients with severe hyperlipidemia25.
In ECD the most frequent CNS symptoms and signs are
central diabetes insipidus that may be the initial symptom of
ECD and may be the only one for many years. Next in
reported frequency are cerebellar symptoms and signs, with
ataxia usually of gait29. Neurologic symptoms are reported in
about one-third of ECD cases. Signs and symptoms such as
pyramidal syndromes, seizures, headaches, neuropsychiatric
or cognitive symptoms, sensory disturbances, cranial nerve
paralysis or even asymptomatic lesions were also reported30.
The prognosis depends on the extent and distribution of
the extraskeletal manifestations. Respiratory distress, extens-
ive pulmonary fibrosis, and cardiac failure are the most com-
mon causes of death31.
Histopathologic findings
ECD is characterized by a mononuclear infiltrate consist-
ing of lipid laden, foamy histiocytes31. In contrast to
Langerhans histiocytosis, lesions of ECD are populated by
histiocytes without nuclear grooves that show CD68 but lit-
tle or no S100 and no CD1a immunoreactivity. Birbeck gran-
ules are also absent32. However, these two diseases may
coexist, and cases of double infiltration with mixed LCH
and ECD have been reported33.
MRI findings and differential
CNS involvement may present as involvement of the
hypothalamic-pituitary axis, brain parenchyma, meninges
or vessels. The HPR manifests as loss of high signal intensity
of the posterior pituitary lobe on T1WI. Another possible
finding ranges from pituitary stalk thickening to a rare
tumorlike mass that can extend to the hypothalamus.
Intraparenchymal involvement is very uncommon and is
evident on MRI as multifocal, diffuse, or infiltrative lesions34.
These lesions are mainly verified at the infratentorial com-
partment (Figure 8), including the brainstem, cerebellum,
and middle cerebellar peduncles, and rarely in the cerebral
Figure 8. A 35-year-old male patient diagnosed with Erdheim-Chester disease. Axial T2WI shows bilateral hyperintensity in the
cerebellar white matter, middle cerebellar peduncles and pons, as well as low signal intensity filling the sphenoid sinus (A and
arrow). Axial T1WI reveals that the lesions are hypointense (B). Gadolinium-enhanced axial T1WI shows enhancement of the
lesions and inside the sphenoid sinus (C). Corresponding axial CT image from a paranasal sinus study reinforces the filling of the
sphenoid sinus associated to the presence of thickened sclerotic walls (D). Bone scintigraphy reveals symmetrically increased
radionuclide uptake at the level of the distal femoral diaphyses and metaphyses, a quite distinctive finding of the disease (E).
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hemispheres30,35,36. The dentate nucleus may show abnormal
symmetric high signal intensity on T2WI that can also be
found in the middle cerebellar peduncles. These lesions pre-
sent variable contrast enhancement and usually little or no
mass effect. If the exact origin of these nongranulomatous
lesions remains unknown, histological examination of these
dentate nuclei lesions can be performed to reveal extensive
loss of myelin sheath tissue, with gliosis and marked sparing
of axons35.
Meningeal lesions and meningioma-like mass lesions:
either a single/multiple dural mass, or diffuse pachymenin-
geal thickening, or even both of those32,35. Parasellar lesions
have also been reported, which may infiltrate the cavernous
sinus22. Although Erdheim-Chester disease rarely affects
spine, it should still be considered in the differential dia-
gnosis of subdural or epidural masses37.
Intracranial periarterial or intravenous infiltrations in
ECD are exceedingly rare, but it may be overlooked because
they can be asymptomatic. These infiltrations should be
detected before catastrophic symptoms related to stroke
develop. Lesions in venous sinuses are extremely rare, which
may be occlusive35.
At MRI, these intracranial masses often had low signal
intensity on T2WI, an isointense signal on T1WI, and
intense homogeneous enhancement on gadolinium-
enhanced T1WI. Intraparenchymal masses may show, less
frequently, a hyperintense signal on T2WI35. The persistent
gadolinium enhancement is a unique distinguishing feature
of Erdheim-Chester disease27. Tien et al.38 first reported the
occurrence of persistent enhancement of intracerebral
masses, after 8 days of administration of gadolinium-based
contrast medium. The precise mechanism is unknown, but
it could be characteristic of abnormal gadolinium retention
by histiocytes36. Some reports demonstrate persistent
enhancement for 2 or more weeks after intravenous Gd-
DTPA administration32. However, although such retention
is seen only in Erdheim-Chester histiocytic lesions, it is
not a universally observed feature27.
The association of intracranial lesions with sinus walls
osteosclerosis with low signal intensity filling and/or orbital
masses are frequent, showing facial and/or skull bone
thickening. Retro-orbital involvement is visualized as either
diffuse masses surrounding the optic nerves or diffuse infil-
tration of the retro-ocular fat, associated with exophthalmia.
These orbital lesions show the same image characteristics
seen on the intracranial lesions35.
HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS
Hemophagocytic lymphohistiocytosis (HLH) is a rare
clinical syndrome characterized by severe hyper-inflam-
mation caused by uncontrolled proliferation and infiltration
of activated lymphocytes and histiocytes. High amounts of
inflammatory cytokines are secreted and multiple organs
are affected, including liver, spleen, lymph nodes, bone mar-
row and the CNS39. This disease, a non-Langerhans cell his-
tiocytosis, also known as hemophagocytic syndrome40, may
be a medical emergency and might lead to a rapid fatal out-
come if not treated promptly and adequately41.
Historically, two forms of HLH are distinguished: genetic
and acquired forms. The genetic (primary) is inherited in an
autosomal recessive or X-linked manner and can be divided
into two subgroups: a) familial HLH (FHLH) in which the
clinical syndrome of HLH is the only manifestation; and b)
the immune deficiencies Chédiak-Higashi syndrome,
Griscelli syndrome and X-linked proliferative syndrome,
which have distinctive clinical features besides the sporadic,
though frequent development of HLH. The FHLH usually
occurs in early infancy in 70-80% of cases, often below one
year of age, and it is found especially in ethnic groups where
consanguineous marriages are common39,42,43.
Acquired (secondary) HLH can occur in all age groups. It
occurs as a reactive process in response to infective agents
as well as to malignancies and tends to occur in immuno-
compromised individuals44. Leading triggering agents in
infection-associated hemophagocytic syndrome are viruses
of the herpes group, especially Epstein-Barr and cytomegalo-
virus. Lymphoma has been reported mostly in adults. A fre-
quent non-viral agent associated with HLH in children is
Leishmania43,45.
The presence of an infection was originally thought to
discriminate between familial and acquired forms.
However, it is now clear that most episodes in the genetic
forms of HLH are also trigged by infections39.
Clinical features and diagnostic criteria
Until recently, it was widely believed that symptoms of
familial hemophagocytic lymphohistiocytosis generally arose
during infancy and early childhood. With the more wide-
spread availability of genetic testing, it is apparent that the
first significant episode of FHLH can occur throughout life,
including in utero.
In the most typical form of FHLH, the clinical course is
characterized by prolonged fever and hepatosplenomegaly.
Although the clinical presentation of HLH is not neuro-
logical in most of the patients, a puzzling neurological onset
may be observed in about 20% of the cases and up to 73% of
affected children ultimately develop CNS involvement.
Neurologic symptoms may dominate the initial clinical
course with seizures and/or ataxia. Neurologic findings
may be highly variable and can include irritability, hypo or
hypertonia, cranial nerve palsies, meningismus, signs of
increased intracranial pressure and altered mental status.
Rash, lymphadenopathy and diarrhea are less frequently
observed. In the early days to months of the disease,
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symptoms may improve spontaneously, followed by clinical
exacerbations. It is important to say that hemophagocytosis
may not be obvious on bone marrow biopsy examination
early in the course of the disease41,46,47.
The main problem is that initially HLH clinical presenta-
tion can mimic a normal infection and too little attention is
dedicated to unusually marked hepatosplenomegaly or
unusually severe blood count changes. Much time then
may be lost with extensive work-up for an infectious disease
or with prolonged antibiotic treatment. Ferritin, triglycer-
ides, and fibrinogen are not routinely determined in children
with fever; HLH has to be kept in mind to order these labor-
atory studies. Also progression of symptoms may be over-
looked or may not be considered unusual. The absence of
hemophagocytosis is often the reason why the diagnosis of
HLH is ruled out. Another problem is that the identification
of an infectious organism may serve to explain all symptoms,
without taking into account that its severity and progression
indicates an immune system deficiency39.
In 1991 the familial haemophagocytic lymphohistiocyto-
sis Study Group of the Histiocyte Society proposed dia-
gnostic guidelines for HLH. They include: fever of ±7 days
duration, splenomegaly, cytopenia affecting at least two cell
lines (hemoglobin ,9.0 g/dL, platelets ,100x109/L, neutro-
phils ,1.0x109/L), hypofibrinogenemia (,1.5 g/L) and/or
hypertriglyceridemia (.2 mmol/l) as well as hemophagocy-
tosis in bone marrow or other tissues48.
Histopathologic findings
Pathologic examination of affected organs shows an infiltra-
tion of benign-appearing histiocytes with hemophagocytosis,
predominantly red blood cells and neutrophils. Bone mar-
row is the tissue most widely used for diagnostic examina-
tion, and bone marrow smears may best demonstrate
hemophagocytosis. Lymph nodes and spleen may reveal
profound generalized lymphoid depletion with sinusoidal
infiltration by hemophagocytic histiocytes in sinusoids.
FHLH may express a characteristic phenotype exhibiting
CD11b, CD21, CD25, CD30, CD 36 and S100 positivity. In
most cases of secondary HLH EBV was found to be the
infectious agent and atypical lymphocytes (with are the
hallmark of acute EBV infection) are absent or diminished,
reflecting a decrease in the number of activated CD8+ T
cells normally seen in response to EBV49.
MRI findings and differential diagnosis
The neurological manifestations are variable and in the
same way the imaging studies do not demonstrate any spe-
cific feature. This can delay the diagnosis, with a high risk of
a sudden severe deterioration and even death41.
Characteristic findings of HLH on brain MRI include mul-
tifocal lesions with or without mass-like lesions that can be
observed in the subcortical areas in the cerebral hemi-
spheres and cerebellum. They may show restricted diffusion,
contrast enhancement (leptomeningeal, nodular or peri-
pheral enhancement) (Figures 9 and 10). Some bleeding
may occur. Diffuse white matter lesions are less common40,50.
Hypoxic ischemic disease, acute disseminated encephalo-
myelitis, cerebrotendinous xanthomatosis, other histiocyto-
sis, mild encephalitis/encephalophathy with reversible
splenium lesion (MERS) are some disease that may be
included in the differential diagnosis40,41.
FINAL REMARKS
Histiocytosis is a group of rare disease with some peculiar-
ities that help to differentiate each one of them. Sometimes,
Figure 9. Patient with 6 months of life presenting bilateral paresis of the sixth cranial nerve, hepatomegaly, increased levels of
ferritin and triglycerides, hypofibrinogenemia and pancytopenia, diagnosed as hemophagocytic lymphohistiocytosis. Axial FLAIR
(A), diffusion-weighted (B) and enhanced T1WI (C) show subtle hyperintense symmetrical deep cerebellar white matter lesions
without restricted diffusion or gadolinium enhancement.
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however, imaging picture can be similar and some overlap in
MRI findings might occur. Some of the most common findings,
like hypothalamic-pituitay axis involvement, meningeal and
meningioma-like mass lesions, choroid plexus lesions, and
intraparenchymal involvement ( for example, high signal intens-
ity on T1-weighted MRI images in cerebellum and basal gan-
glia) must be recognized to include this possibility in the
differential diagnosis, whenever considered pertinent.
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